Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
How would you manage an elderly patient with clinical stage IIIC ER positive breast cancer who refuses surgery, chemo and radiation treatment and willing to take only oral medications?
My approach would be to start the patient on an aromatase inhibitor. Since this treatment would not be considered curable and treatment goal would be palliative, a case can be made for consideration of adding CDK 4/6 inhibitor, especially if her disease is considered inoperable due to advance stage.
What is your approach to tamoxifen use in women who are unable to discontinue a strong CYP2D6 inhibitor and who are unable to use or tolerate an AI?
I ran into this very situation not too long ago. In dealing with the situation, I asked myself the following questions: 1) Did I speak to prescribing psychiatrist or psychopharmacologist (or if I was the prescriber or primary care provider refer to a more experienced physician?) 2) Did I do everythi...
What adjuvant chemotherapy would you recommend in a premenopausal patient with pT1cN1 HR+ breast cancer who previously received an anthracycline and cyclophosphamide 30 years prior?
I would defer anthracycline regimens since the risk of cardiomyopathy increases after cumulative dose doxorubicin exceeds 400-450 mg/m2. Her prior exposure to alkylating agents also puts her at risk for secondary MDS from cyclophosphamide which is pretty much present in all modern chemotherapy regim...
What is your approach to chemoprevention for HR+ DCIS in the ipsilateral breast in a patient who already completed 7 years of an AI for a prior HR+ invasive breast cancer?
This is a not-uncommon scenario. What is the appropriate use of endocrine therapy after ipsilateral breast tumor recurrence or second primary breast cancer in a patient who has recently completed hormonal therapy?As shown in the Breast Cancer Prevention Trial (P-1), MAP.3, and IBIS II, both SERMs an...
Do you prefer using an anthracycline or non-anthracycline adjuvant regimen in BRCA+ premenopausal patients with localized HR+ breast cancer?
My choice of chemotherapy for localized BRCA+ breast cancer is guided by the patient's risk factors such as tumor grade, tumor size, presence or absence of lymphovascular invasion, number of lymph nodes involved, Oncotype dx result, and the patient's age. For small, node negative, HR+, HER2- breast ...
Would you treat a Stage I ER/PR positive HER2 negative breast cancer differently if it is associated with Lynch syndrome?
In reviewing the literature, there are a number of articles describing the risk of breast cancer in patients with Lynch syndrome such as this: (Nikitin et al., PMID 32547938). The cliff notes are that in patients with Lynch syndrome and certain mutations, there appears to be a small but definite inc...
How would you continue management of a patient with clinical stage II cN+ HR+ HER2+IDC with grade 3 diarrhea after 1 cycle of neoadjuvant TCHP?
Diarrhea is very common with TCHP, with about 70% of patients having diarrhea and 10% having diarrhea grade 3 or higher. Pertuzumab is the primary culprit, although diarrhea is more common when this is combined with chemotherapy. I would assure adequate hydration and replace electrolytes as appropri...
What adjuvant treatment approach would you choose for a premenopausal woman with lymph node positive poorly differentiated metaplastic breast cancer that is ER low+, PR+, HER2 negative?
Given the tumor is ER low+ (and I'm going to assume not strongly PR+ in this case since that would be highly unusual in the setting of ER low positivity only...but please comment back if I'm wrong!), yes, I would consider this biologically triple-negative disease (and very high risk given metaplasti...
In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?
This is an open question. As has been true in oncology for some time, most of the adjuvant therapies we offer have shown benefit first in the metastatic setting, and then are tested in the adjuvant setting. Abemaciclib has been shown to have benefit when combined with herceptin and endocrine therapy...
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
The SOFT/TEXT data showed that the patients who benefited from ovarian suppression + endocrine therapy were those who were <35 years old or those who had prior chemotherapy (essentially those patients who were deemed to have high risk disease). The TAILORx study demonstrated that patients with recur...